The primary driver of the chronic bronchitis market is the rising occurrence of mutations in the dystrophin gene, disrupting essential structural and signaling functions within muscle cells.

1. Chronic Bronchitis
Market Research
Report 2023-2033

2. ABOUT IMARC
2
International Market Analysis Research and Consulting Group is a
leading adviser on management strategy and market research
worldwide. We partner with clients in all regions and industry
verticals to identify their highest-value opportunities, address their
most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific,
economic and technological developments for business leaders in
pharmaceutical, industrial, and high technology organizations.
Market forecasts and industry analysis for biotechnology, advanced
materials, chemicals, food and beverage, travel and tourism,
nanotechnology and novel processing methods are at the top of
the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into
the dynamics of companies and markets with close cooperation at
all levels of the client organization. This ensures that our clients
achieve unmatchable competitive advantage, build more proficient
organizations, and secure lasting results.

3. Report Description and Highlights
Chronic Bronchitis Market 2023-2033
The newly published report by IMARC Group, titled ”Chronic Bronchitis Market: Epidemiology, Industry Trends, Share, Size, Growth,
Opportunity, and Forecast 2023-2033″, presents a comprehensive analysis of the chronic bronchitis market. The report provides an
overview of the market trends, growth prospects, investment opportunities, and industry prospects, as well as an analysis of the disease
overview, market scenario, and growth trends. In addition, the report offers competitor analysis, regional analysis, and recent
advancements in the seven major markets (7MM). The report also highlights key segments and market drivers, as well as challenges faced
by industry players.
Chronic Bronchitis Market Size:
The chronic bronchitis market is anticipated to grow at a CAGR of 2.8% during 2023-2033
Request a Sample Report: https://www.imarcgroup.com/chronic-bronchitis-market/requestsample
3

4. Report Description and Highlights
What is Chronic Bronchitis?
Becker muscular dystrophy (BMD) is a genetic disorder characterized by the progressive deterioration and weakness of muscles. Symptoms
typically manifest in late childhood or adolescence but can occur at any age. The most evident symptom is a steady and rapid muscle
weakness impacting the hips, pelvic area, thighs, arms, legs, and heart. Other common indications include walking difficulties, a waddling
gait, recurrent falls, enlargement of calf muscles, and cramping.
As the condition advances, patients may develop contractures indicative of joint stiffness and experience respiratory issues. BMD can be
diagnosed by clinical evaluation, examination of family history, and physical examination. Healthcare providers may also conduct a muscle
biopsy or perform genetic testing, such as deoxyribonucleic acid (DNA) sequencing or multiplex ligation-dependent probe amplification, to
identify genetic mutations or alterations contributing to the disorder.
4

5. Report Description and Highlights
What are the key drivers and trends in the Chronic Bronchitis market?
The primary driver of the chronic bronchitis market is the rising occurrence of mutations in the dystrophin gene, disrupting essential
structural and signaling functions within muscle cells. In addition to this, the increasing utilization of corticosteroids such as prednisone and
deflazacort, known to decelerate muscle degeneration and enhance strength in patients, is contributing to the market’s growth.
Moreover, the expanding adoption of assistive devices, such as braces, splints, and orthotics, to provide support, maintain joint alignment,
and prevent contractures in BMD patients, is propelling the market forward. Besides this, the surging application of physical and
occupational therapies, aiming to boost functional abilities and promote independence through exercises and stretches, are aiding in
market expansion. Furthermore, the emerging trend of gene therapy, which involves delivering functional copies of the defective gene
directly into affected cells to restore the production of a full-length dystrophin protein, is strengthening the market growth.
5

6. Report Description and Highlights
What is included in the report segmentation?
The report covers the following aspects:
Report Period:
• Base Year: 2022
• Historical Period: 2017-2022
• Market Forecast: 2023-2033
Countries Included:
• United States
• Germany
• France
6

7. Report Description and Highlights
• United Kingdom
• Italy
• Spain
• Japan
Analysis Covered Across Each Country
• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the Chronic Bronchitis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the Chronic Bronchitis market
• Reimbursement scenario in the market
• In-market and pipeline drugs
7

8. Report Description and Highlights
In-Market Drugs
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Regulatory Status
View Report TOC, Figures and Tables: https://www.imarcgroup.com/chronic-bronchitis-market
8

9. Key Questions Answered in the Report
1. How has the Chronic Bronchitis market performed so far and how will it perform in the coming years?
2. What are the markets shares of various therapeutic segments in 2022 and how are they expected to perform till 2033?
3. What was the country-wise size of the Chronic Bronchitis market across the seven major markets in 2022 and what will it look like in
2033?
4. What is the growth rate of the Chronic Bronchitis market across the seven major markets and what will be the expected growth over
the next ten years?
5. What are the key unmet needs in the market?
9

10. Table of
Contents

11. Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
11

12. Table of Contents
4 Chronic Bronchitis - Introduction
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2017-2022) and Forecast (2023-2033)
4.4 Market Overview (2017-2022) and Forecast (2023-2033)
4.5 Competitive Intelligence
5 Chronic Bronchitis - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
Click here to visit the complete table of content with list of figures and tables: https://www.imarcgroup.com/chronic-bronchitis-
market/toc
12

13. Partial List Of Our Clients
13

14. OUR CLIENTS
14

15. Disclaimer
15
© 2023 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis
Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or
in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including
photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information
and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting
makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts
no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and
Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.